{"id":"telomerase-peptide-vaccine-gv1001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4297811","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Telomerase is an enzyme that maintains telomeres, the protective caps on chromosome ends. In cancer cells, telomerase is often overexpressed, allowing these cells to divide indefinitely. GV1001, a telomerase peptide vaccine, aims to induce an immune response against telomerase, potentially slowing or stopping cancer cell growth.","oneSentence":"GV1001 works by stimulating an immune response against telomerase, a protein often overexpressed in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:56.923Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05303701","phase":"PHASE3","title":"GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)","status":"NOT_YET_RECRUITING","sponsor":"Samsung Pharmaceutical Co., Ltd.","startDate":"2027-07","conditions":"Moderate to Severe Alzheimer's Disease","enrollment":750},{"nctId":"NCT05819658","phase":"PHASE2","title":"GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2023-06-14","conditions":"Progressive Supranuclear Palsy","enrollment":78},{"nctId":"NCT06235775","phase":"PHASE2","title":"Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2023-12-12","conditions":"Progressive Supranuclear Palsy","enrollment":67},{"nctId":"NCT06625710","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2024-10-08","conditions":"Neuro-Degenerative Disease","enrollment":59},{"nctId":"NCT05189210","phase":"PHASE2","title":"GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2022-10-05","conditions":"Mild to Moderate Alzheimer's Disease","enrollment":199},{"nctId":"NCT04032067","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2019-10-30","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":423},{"nctId":"NCT02855892","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2015-10","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":161},{"nctId":"NCT03959553","phase":"PHASE2","title":"GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)","status":"WITHDRAWN","sponsor":"GemVax & Kael","startDate":"2019-09-01","conditions":"Moderate Alzheimer's Disease","enrollment":""},{"nctId":"NCT03184467","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2017-09-05","conditions":"Alzheimer Disease","enrollment":96},{"nctId":"NCT01342224","phase":"PHASE1","title":"Immunochemoradiotherapy in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2011-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":11},{"nctId":"NCT02854072","phase":"PHASE3","title":"A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients","status":"UNKNOWN","sponsor":"Samsung Pharmaceutical Co., Ltd.","startDate":"2015-11","conditions":"Pancreatic Cancer","enrollment":148},{"nctId":"NCT01247623","phase":"PHASE1, PHASE2","title":"Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2005-01","conditions":"Malignant Melanoma","enrollment":""},{"nctId":"NCT00425360","phase":"PHASE3","title":"Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Royal Liverpool University Hospital","startDate":"2006-09","conditions":"Pancreatic Cancer","enrollment":1110},{"nctId":"NCT01579188","phase":"PHASE3","title":"Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Kael-GemVax Co., Ltd.","startDate":"2012-05","conditions":"Inoperable Stage III Non-small Cell Lung Cancer","enrollment":600},{"nctId":"NCT01223209","phase":"PHASE1","title":"A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma","status":"COMPLETED","sponsor":"Lytix Biopharma AS","startDate":"2010-08","conditions":"Carcinoma","enrollment":12},{"nctId":"NCT00444782","phase":"PHASE2","title":"A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.","status":"COMPLETED","sponsor":"Pharmexa A/S","startDate":"2006-11","conditions":"Carcinoma, Hepatocellular","enrollment":41},{"nctId":"NCT00358566","phase":"PHASE3","title":"GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer","status":"TERMINATED","sponsor":"Pharmexa A/S","startDate":"2006-06","conditions":"Advanced Unresectable Pancreatic Cancer","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"telomerase peptide vaccine GV1001","genericName":"telomerase peptide vaccine GV1001","companyName":"Royal Liverpool University Hospital","companyId":"royal-liverpool-university-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"GV1001 works by stimulating an immune response against telomerase, a protein often overexpressed in cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}